Stoneridge (SRI)
(Delayed Data from NYSE)
$7.74 USD
+0.53 (7.35%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $7.73 -0.01 (-0.13%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.74 USD
+0.53 (7.35%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $7.73 -0.01 (-0.13%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
Zacks News
Earnings Preview: Stoneridge (SRI) Q4 Earnings Expected to Decline
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoneridge (SRI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Stoneridge (SRI) delivered earnings and revenue surprises of 200.00% and 15.14%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Stoneridge (SRI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Toxic Stocks to Discard From Your Portfolio Right Now
by Rimmi Singhi
If you own a toxic stock for long, you are likely to see a big loss in your wealth. Discarding them at the right time is the key to shield your portfolio from big losses.
Zacks.com featured highlights include: HealthEquity, Alarm.com, Stoneridge, Mercer and Bottomline Technologies
by Zacks Equity Research
Zacks.com featured highlights include: HealthEquity, Alarm.com, Stoneridge, Mercer and Bottomline Technologies
Analysts Estimate Stoneridge (SRI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 5 Toxic Stocks Could be Poisoning Your Portfolio
by Zacks Equity Research
Investors who can figure out the overpriced toxic stocks and shun them at the right time are the ones that are likely to benefit.
Zacks.com featured highlights include: Cushman Wakefield, Stoneridge, Bottomline Technologies, New Fortress Energy and Trinseo
by Zacks Equity Research
Zacks.com featured highlights include: Cushman Wakefield, Stoneridge, Bottomline Technologies, New Fortress Energy and Trinseo
5 Toxic Stocks to Get Rid Of or Play Short to Make Gains
by Zacks Equity Research
Figuring out toxic stocks and abandoning them at the right time is the key to shield your portfolio from big losses.
Earnings Preview: Stoneridge (SRI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for December 26th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for December 23rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Bleak Outlook for Electronics Miscellaneous Components Stocks
by Shalu Saraf
Electronics - Miscellaneous Components stocks are being impacted by trade war tensions. However, strong demand for electronic components will likely benefit the industry participants.
Twitter (TWTR) Q3 Earnings Miss, User Growth Aids Top Line
by Zacks Equity Research
Twitter's (TWTR) third-quarter 2019 results reflect product-related issues and higher-than-expected ad seasonality despite user growth.
MKS Instruments' (MKSI) Q3 Earnings Beat, Revenues Miss
by Zacks Equity Research
MKS Instruments' (MKSI) third-quarter 2019 results reflect weakness in the semiconductor market despite higher advanced market revenues.
Earnings Preview: Stoneridge (SRI) Q3 Earnings Expected to Decline
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SRI or NJDCY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SRI vs. NJDCY: Which Stock Is the Better Value Option?
Earnings Preview: Stoneridge (SRI) Q3 Earnings Expected to Decline
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SRI or OLED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SRI vs. OLED: Which Stock Is the Better Value Option?
Is Stoneridge (SRI) A Great Pick for Value Investors?
by Zacks Equity Research
Is Stoneridge (SRI) a great pick from the value investor's perspective right now? Read on to know more.
Earnings Preview: Stoneridge (SRI) Q2 Earnings Expected to Decline
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Stoneridge (SRI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoneridge (SRI) Reports Next Week: What Awaits?
by Zacks Equity Research
Stoneridge (SRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoneridge (SRI) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stoneridge (SRI) delivered earnings and revenue surprises of 9.30% and 2.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Moving Average Crossover Alert: Stoneridge (SRI)
by Zacks Equity Research
Stoneridge, Inc. (SRI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front